At LSX 2024 in Boston last month, editor-in-chief Jonah Comstock spoke with James Graham, CEO and founder of Recce Pharma, an Australian start-up creating a new antibiotic for sepsis, focusing in ...

especially considering the high degree of bacterial resistance present in many of the patients being treated in this Phase II trial,” said James Graham, CEO of Recce Pharmaceuticals.

RECCE 327 developed by Recce Pharmaceuticals ... Even when bacteria attempt to mutate, the antibiotic continues to work,” said VP James Graham. Traditionally, antibiotics have come from natural ...